Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A comprehensive meta-analysis of over 260,000 infants confirms that nirsevimab significantly reduces respiratory syncytial virus (RSV) and lower respiratory tract infection (LRTI) hospitalizations and emergency department visits, providing
Recent real-world data from the US and France indicate that while both maternal RSV vaccination and nirsevimab are effective, nirsevimab may offer superior protection against hospitalization and intensive care admission for infants in their
A multicenter test-negative case-control study in France found high and sustained effectiveness of nirsevimab against RSV bronchiolitis in infants across two consecutive seasons (83.2% and 89.3%), despite emergence of RSV-B mutations.
Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory
A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to preven
A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12
Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from